Formulary
Levodopa (+ Carbidopa): Uses, Dosing, Side Effects and Indian Brand Names
Levodopa-carbidopa is the most effective treatment for Parkinson's disease. Levodopa crosses the BBB and is converted to dopamine centrally, while carbidopa prevents peripheral conversion. Long-term use leads to wearing-off, on-off fluctuations, and dyskinesias.
MedNext Academy | 5 min read
Clinically reviewed by Awaiting clinical review
Levodopa (+ Carbidopa): Uses, Dosing, Side Effects and Indian Brand Names
Levodopa-carbidopa is the most effective treatment for Parkinson's disease. Levodopa crosses the BBB and is converted to dopamine centrally, while carbidopa prevents peripheral conversion. Long-term use leads to wearing-off, on-off fluctuations, and dyskinesias.
NEET PG High-Yield: Levodopa is the most effective drug for Parkinson's disease but is NOT a cure (does not halt neurodegeneration). Wearing-off and dyskinesia after 2-5 years is the classic complication. Carbidopa prevents peripheral side effects but does NOT cross the BBB. Non-selective MAOIs are ABSOLUTELY contraindicated (hypertensive crisis). Drug holiday is OUTDATED and dangerous -- never recommended.
Clinical overview
The levodopa-carbidopa combination is the most effective drug therapy for Parkinson's disease and remains the gold standard against which all other antiparkinsonian drugs are compared. Levodopa is dramatically effective in relieving the cardinal symptoms of Parkinson's -- bradykinesia, rigidity, and tremor -- with bradykinesia responding the best. However, after 2-5 years of therapy, most patients develop motor complications: the 'wearing-off' phenomenon (end-of-dose deterioration), 'on-off' fluctuations (unpredictable swings between mobility and immobility), and levodopa-induced dyskinesia (choreiform involuntary movements during peak plasma levels). These long-term complications have led to the clinical debate of whether to start levodopa early or defer it in young patients (using dopamine agonists as initial monotherapy in patients under 65-70 years). In Indian neurology practice, levodopa-carbidopa is universally available and affordable, and is the first drug initiated in patients over 70 years and in those with significant functional impairment. Dietary protein competes with levodopa for absorption via large neutral amino acid transporters in the gut and at the blood-brain barrier, and patients should take the drug 30 minutes before meals.
Pharmacological class
Levodopa (+ Carbidopa) belongs to the Dopamine precursor + peripheral decarboxylase inhibitor (anti-Parkinsonian) class. Levodopa is the metabolic precursor of dopamine that crosses the blood-brain barrier (dopamine itself cannot). In the brain, it is decarboxylated to dopamine by aromatic L-amino acid decarboxylase (DOPA decarboxylase), replenishing depleted dopamine in the nigrostriatal pathway. Carbidopa is a peripheral DOPA decarboxylase inhibitor that prevents peripheral conversion of levodopa to dopamine (which causes nausea and hypotension), thereby increasing CNS bioavailability from ~1% to ~10% and reducing the required levodopa dose by 75%.
Indian brand names and formulations
Available as: Syndopa (Sun Pharma), Tidomet (Merind/Wockhardt), Sinemet (MSD/Organon), Madopar (Roche) [levodopa + benserazide].
Tablets -- Carbidopa/Levodopa: 10/100 mg, 25/100 mg, 25/250 mg. Controlled-release tablets: 25/100 mg CR, 50/200 mg CR. Triple combination (with entacapone): Stalevo equivalent. Dispersible tablets for patients with swallowing difficulty.
Regulatory status
Levodopa (+ Carbidopa) is classified under Schedule H in India under the Drugs and Cosmetics Act, 1940. Schedule H prescription drug. Available in multiple fixed-dose combinations with carbidopa (and with entacapone in triple combination). NLEM 2022 listed.
Indications
- Parkinson's disease (most effective drug for all motor symptoms)
- Parkinsonian syndromes (drug-induced parkinsonism -- only after stopping offending drug)
- Restless legs syndrome (low doses; limited by augmentation)
- Dopa-responsive dystonia (Segawa disease -- dramatic response)
Dosing
Start: Carbidopa/Levodopa 25/100 mg TDS, taken 30 minutes before meals. Titrate gradually every 3-7 days. Usual maintenance: 75/300 to 200/800 mg/day in 3-4 divided doses. The carbidopa component should be at least 75 mg/day for effective peripheral blockade. CR formulation: used for wearing-off, dosed BD-TDS. In advanced disease: smaller, more frequent doses, or add COMT inhibitor (entacapone) or MAO-B inhibitor (selegiline/rasagiline). Protein restriction at mealtimes may improve absorption.
Contraindications
- Concurrent use with non-selective MAO inhibitors (hypertensive crisis -- wait 14 days; selective MAO-B inhibitors like selegiline are safe)
- Narrow-angle glaucoma
- Malignant melanoma or suspicious undiagnosed skin lesions
- Psychotic disorders (may worsen due to dopaminergic stimulation)
Adverse effects
- Nausea and vomiting (due to stimulation of CTZ -- reduced by carbidopa)
- Orthostatic hypotension (peripheral dopamine effect -- improved by carbidopa)
- Dyskinesia (peak-dose choreiform movements -- most troublesome long-term complication)
- Wearing-off phenomenon (end-of-dose deterioration of motor function)
- On-off fluctuations (unpredictable motor fluctuations in advanced disease)
- Psychiatric effects: vivid dreams, visual hallucinations, psychosis (dopaminergic overstimulation)
- Impulse control disorders (compulsive gambling, hypersexuality -- more common with dopamine agonists)
- Darkening of urine and sweat (harmless melanin metabolite)
Drug interactions
- Non-selective MAO inhibitors (phenelzine, tranylcypromine) -- hypertensive crisis (ABSOLUTE CONTRAINDICATION)
- Antipsychotics (haloperidol, chlorpromazine) -- mutual antagonism; block dopamine receptors, worsen parkinsonism
- Pyridoxine (vitamin B6) -- enhances peripheral decarboxylation, reducing CNS levodopa levels (this effect is blocked by carbidopa)
- Iron and antacids -- reduce levodopa absorption (separate by 2 hours)
- High-protein meals -- competitive absorption at large neutral amino acid transporters
- Isoniazid -- may reduce levodopa efficacy
Pregnancy and lactation
Category C. Limited human data. Animal studies show skeletal and visceral abnormalities. Use only if the potential benefit justifies the risk. Most women with Parkinson's disease are beyond reproductive age, so this is rarely a clinical issue.
Exam-style clinical scenario
A 68-year-old man with Parkinson's disease on levodopa-carbidopa for 5 years reports that his medication effect wears off 2-3 hours before the next dose, with return of tremor and stiffness. He also develops involuntary writhing movements of his limbs 1 hour after taking each dose. What is happening and how should it be managed? Answer: He is experiencing both wearing-off phenomenon (end-of-dose deterioration) and peak-dose dyskinesia. Management options: (1) Reduce individual levodopa doses but increase frequency, (2) Add a COMT inhibitor (entacapone) to extend levodopa duration, (3) Add a MAO-B inhibitor (rasagiline) to reduce dopamine breakdown, (4) Switch to controlled-release formulation. Amantadine can specifically reduce dyskinesia.
Cost in India
INR 40-80 per strip of 10 tablets (25/100 mg); CR formulation: INR 50-100
Clinical governance
Author: MedNext Editorial Team. Clinical reviewer: Awaiting clinical review. Jurisdiction: India (Drugs and Cosmetics Act, 1940). Sources: CIMS India, Indian Pharmacopoeia. Publication state: Awaiting clinical review. Correction: Report errors at support@mednext.academy.
Frequently Asked Questions
Why does levodopa become less effective after years of use?
As Parkinson's disease progresses, dopaminergic neurons continue to degenerate, reducing the brain's capacity to store and release dopamine synthesised from levodopa. With fewer neurons, dopamine levels become directly dependent on plasma levodopa levels, causing motor fluctuations. Additionally, postsynaptic dopamine receptor sensitivity changes may contribute to dyskinesia. This is the basis for the 'continuous dopaminergic stimulation' hypothesis.
Why is levodopa given with carbidopa rather than alone?
Without carbidopa, approximately 95% of levodopa is decarboxylated to dopamine in the periphery (gut, liver, blood vessels), causing severe nausea, vomiting, and hypotension, while only ~1% reaches the brain. Carbidopa blocks peripheral DOPA decarboxylase (it cannot cross the BBB, so it does not affect central conversion), increasing CNS bioavailability to ~10% and reducing the required levodopa dose by 75%.
Should levodopa be started early or delayed in young Parkinson's patients?
This is a debated question. Current evidence suggests: in patients under 65-70 years, many neurologists start with a dopamine agonist (pramipexole, ropinirole) to delay the onset of levodopa-related motor complications. In patients over 70, levodopa is started first because dopamine agonists cause more psychiatric side effects in the elderly. However, levodopa should never be withheld if the patient has significant functional disability, regardless of age.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
Test yourself on Levodopa (+ Carbidopa)
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary